Carisma Therapeutics Inc (CARM) Actualités

Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024

Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of...

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma PR...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights PR...

CARMILA: Information Concerning the Total Number of Voting Rights and Share

Provided pursuant to article L.233-8 II of the Code de commerce (French Commercial Code) and article 223-16 of the Règlement général de...

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Carisma Therapeutics Announces Changes to its Board of Directors

Carisma Therapeutics Announces Changes to its Board of Directors PR Newswire PHILADELPHIA, Oct. 30, 2024...

Carmila: Third-quarter 2024 Financial Information

Key financial information: Sustained growth in net rental income of 6.2% (up 3.6% like-for-like) compared with the first nine months of 2023...

CARMILA : COMMUNIQUÉ DE PRESSE EN DATE DU 16 OCTOBRE 2024

MISE EN ŒUVRE DU RETRAIT OBLIGATOIRE DE LA SOCIÉTÉ GALIMMO SCA INITIÉE PAR LA SOCIETE CARMILA Regulatory News: Carmila (Paris:CARM) : Ne pas...